MCID: ADL053
MIFTS: 35

Adult Astrocytic Tumour malady

Categories: Cancer diseases

Aliases & Classifications for Adult Astrocytic Tumour

Aliases & Descriptions for Adult Astrocytic Tumour:

Name: Adult Astrocytic Tumour 12 14
Adult Astrocytic Tumors 69
Adult Astrocytoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3076
NCIt 47 C7049
UMLS 69 C1332183

Summaries for Adult Astrocytic Tumour

MalaCards based summary : Adult Astrocytic Tumour, also known as adult astrocytic tumors, is related to optic disk drusen and enterovesical fistula. An important gene associated with Adult Astrocytic Tumour is ATRX (ATRX, Chromatin Remodeler), and among its related pathways/superpathways are Degradation of the extracellular matrix and IL-17 Family Signaling Pathways. The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Related phenotype is neoplasm.

Related Diseases for Adult Astrocytic Tumour

Diseases related to Adult Astrocytic Tumour via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 61)
id Related Disease Score Top Affiliating Genes
1 optic disk drusen 10.3 IDH1 IDH2
2 enterovesical fistula 10.3 IDH1 IDH2
3 acrocallosal syndrome 10.3 IDH1 IDH2
4 neurilemmoma 10.3 IDH1 IDH2
5 testis refractory cancer 10.3 IDH1 IDH2
6 cystinosis, nephropathic 10.3 IDH1 IDH2
7 small cell osteogenic sarcoma 10.2 IDH1 IDH2
8 glycogen storage disease type 0 10.2 IDH1 IDH2
9 angioma hereditary neurocutaneous 10.2 IDH1 IDH2
10 neuropathy, ataxia, and retinitis pigmentosa 10.2 IDH1 IDH2
11 breast papillomatosis 10.2 IDH1 IDH2
12 spinal cord astrocytoma 10.2 IDH1 IDH2
13 prosopagnosia 10.2 IDH1 IDH2
14 agammaglobulinemia 8, autosomal dominant 10.2 IDH1 IDH2
15 gummatous syphilis 10.2 IDH1 IDH2
16 amyloid tumor 10.2 IDH1 IDH2
17 calciphylaxis 10.2 H3F3A H3F3B
18 symmastia 10.2 MMP1 MMP3
19 bronchial mucus gland adenoma 10.2 IDH2 PTEN
20 hemangioma of liver 10.1 H3F3A H3F3B
21 hair disease 10.1 H3F3A H3F3B
22 angiomyoma 10.1 MMP1 MMP3
23 childhood embryonal testis carcinoma 10.1 IDH1 PTEN
24 acute tricyclic antidepressant poisoning 10.1 MMP7 MMP9
25 tinea profunda 10.0 MMP7 MMP9
26 fecal incontinence 10.0 MMP1 MMP3
27 right atrium familial dilatation 10.0 MMP3 MMP9
28 brain meningioma 10.0 MMP7 MMP9
29 cutaneous adenocystic carcinoma 10.0 H3F3A H3F3B IDH1
30 pasteurellosis 10.0 MMP1 MMP3
31 cortical blindness mental retardation polydactyly 10.0 MMP1 MMP3 MMP7
32 central nervous system adult germ cell tumor 10.0 MMP3 MMP9
33 adult oligodendroglioma 10.0 IDH1 IDH2 PTEN
34 penis agenesis 10.0 MMP7 MMP9
35 cellulitis 10.0 MMP3 MMP9
36 adult-onset distal myopathy due to vcp mutation 10.0 MMP1 MMP9
37 diffuse large b-cell lymphoma 10.0 MMP1 MMP9
38 idiopathic corneal edema 10.0 MMP1 MMP3
39 ectropion 10.0 MMP1 MMP9
40 schwannomatosis 10.0 MMP3 MMP9
41 retinal artery occlusion 9.9 MMP3 MMP9
42 chondrodysplasia punctata, rhizomelic, type 1 9.9 MMP3 MMP7 MMP9
43 adult neuronal ceroid lipofuscinosis 9.9 MMP1 MMP9
44 senile atrophy of choroid 9.9 MMP1 MMP7 MMP9
45 linear porokeratosis 9.9 MMP1 MMP7 MMP9
46 astrocytoma 9.9
47 lower lip cancer 9.8 MMP7 MMP9 PTEN
48 mixed ductal-endocrine carcinoma 9.8 MMP1 MMP3 MMP9
49 histiocytosis 9.8 MMP1 MMP3 MMP9
50 proctitis 9.8 MMP7 MMP9 PTEN

Graphical network of the top 20 diseases related to Adult Astrocytic Tumour:



Diseases related to Adult Astrocytic Tumour

Symptoms & Phenotypes for Adult Astrocytic Tumour

MGI Mouse Phenotypes related to Adult Astrocytic Tumour:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.02 IDH2 MMP1 MMP7 MMP9 PTEN

Drugs & Therapeutics for Adult Astrocytic Tumour

Drugs for Adult Astrocytic Tumour (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 592)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
3
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
4 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
5 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
6 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
7
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 498142 38904
8
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
9
Etoposide Approved Phase 2, Phase 3, Phase 1 33419-42-0 36462
10
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
11
Thiotepa Approved Phase 2, Phase 3, Phase 1 52-24-4 5453
12
Tranexamic Acid Approved Phase 3 1197-18-8 5526
13
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
14
Lomustine Approved Phase 3,Phase 2,Phase 1 13010-47-4 3950
15
Procarbazine Approved Phase 3,Phase 2,Phase 1 671-16-9 4915
16
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
17
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
18
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
19
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
20
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
21
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
22
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
23
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
24
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 97682-44-5, 100286-90-6 60838
25
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
26
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
27
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
28
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
29
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
30
Ethanol Approved Phase 2, Phase 3,Phase 1,Early Phase 1 64-17-5 702
31
Aminolevulinic acid Approved Phase 3,Phase 1,Phase 2 106-60-5 137
32
Sunitinib Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 341031-54-7, 557795-19-4 5329102
33
Hydroxychloroquine Approved Phase 2, Phase 3,Phase 1 118-42-3 3652
34
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
35
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
36
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
37
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
38
Leflunomide Approved, Investigational Phase 3,Phase 2 75706-12-6 3899
39
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
40
chloroquine Approved, Vet_approved Phase 3,Phase 2,Phase 1 54-05-7 2719
41
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
42
Copper Approved Phase 2, Phase 3,Phase 1,Early Phase 1 15158-11-9, 7440-50-8 27099
43
Flucytosine Approved Phase 2, Phase 3,Phase 1 2022-85-7 3366
44
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
45
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
46
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
47
Disulfiram Approved Phase 2, Phase 3,Phase 1,Early Phase 1 97-77-8 3117
48
Dopamine Approved Phase 3,Phase 1,Phase 2 51-61-6, 62-31-7 681
49
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
50
Granisetron Approved, Investigational Phase 3 109889-09-0 3510

Interventional clinical trials:

(show top 50) (show all 1289)
id Name Status NCT ID Phase
1 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4
2 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4
3 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
4 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
5 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3
6 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3
7 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3
8 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3
9 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3
10 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Unknown status NCT01149109 Phase 3
11 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3
12 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3
13 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3
14 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3
15 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3
16 Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Completed NCT00789828 Phase 3
17 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3
18 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3
19 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
20 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3
21 Nimotuzumab in Adults With Glioblastoma Multiforma Completed NCT00753246 Phase 3
22 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3
23 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
24 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3
25 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3
26 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3
27 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3
28 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3
29 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3
30 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3
31 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3
32 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3
33 An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies Completed NCT00226655 Phase 3
34 XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors Completed NCT00088166 Phase 3
35 Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Completed NCT00790400 Phase 3
36 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3
37 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3
38 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Completed NCT01450449 Phase 3
39 A Study of Avastin® (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3
40 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3
41 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Completed NCT00777153 Phase 3
42 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed NCT00689221 Phase 3
43 Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) Completed NCT00379470 Phase 3
44 Enzastaurin Versus Lomustine in Glioblastoma Completed NCT00295815 Phase 3
45 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3
46 Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme Completed NCT00068952 Phase 3
47 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3
48 Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors Completed NCT00088400 Phase 3
49 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3
50 Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients Recruiting NCT02796261 Phase 3

Search NIH Clinical Center for Adult Astrocytic Tumour

Genetic Tests for Adult Astrocytic Tumour

Anatomical Context for Adult Astrocytic Tumour

Publications for Adult Astrocytic Tumour

Articles related to Adult Astrocytic Tumour:

id Title Authors Year
1
p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours. ( 18781178 )
2008
2
Galectin-3 and galectin-3-binding site expression in human adult astrocytic tumours and related angiogenesis. ( 10476049 )
1999

Variations for Adult Astrocytic Tumour

Expression for Adult Astrocytic Tumour

Search GEO for disease gene expression data for Adult Astrocytic Tumour.

Pathways for Adult Astrocytic Tumour

Pathways related to Adult Astrocytic Tumour according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.43 MMP1 MMP3 MMP7 MMP9
2
Show member pathways
12.03 MMP1 MMP3 MMP9
3 11.89 MMP1 MMP7 MMP9
4 11.88 H3F3A H3F3B MMP3 MMP9
5 11.67 MMP1 MMP3 MMP9
6 11.52 MMP3 MMP7 MMP9
7
Show member pathways
11.45 MMP1 MMP3 MMP7 MMP9
8
Show member pathways
11.34 MMP1 MMP3 MMP9
9 11.07 MMP1 MMP9
10 11.03 H3F3A H3F3B
11 11.02 MMP1 MMP3 MMP9
12 10.71 MMP1 MMP3 MMP7 MMP9
13
Show member pathways
10.57 IDH1 IDH2
14 10.36 MMP1 MMP7 MMP9

GO Terms for Adult Astrocytic Tumour

Cellular components related to Adult Astrocytic Tumour according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 proteinaceous extracellular matrix GO:0005578 9.62 MMP1 MMP3 MMP7 MMP9
2 extracellular matrix GO:0031012 9.56 MMP1 MMP3 MMP7 MMP9
3 nuclear chromosome, telomeric region GO:0000784 9.54 ATRX H3F3A H3F3B
4 nuclear nucleosome GO:0000788 9.4 H3F3A H3F3B
5 extracellular region GO:0005576 9.23 H3F3A H3F3B IDH1 MMP1 MMP3 MMP7
6 Barr body GO:0001740 9.16 H3F3A H3F3B
7 nuclear chromosome GO:0000228 9.13 ATRX H3F3A H3F3B

Biological processes related to Adult Astrocytic Tumour according to GeneCards Suite gene sharing:

(show all 21)
id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.77 H3F3A H3F3B MMP1
2 nucleosome assembly GO:0006334 9.69 ATRX H3F3A H3F3B
3 multicellular organism growth GO:0035264 9.67 ATRX H3F3A H3F3B
4 embryo implantation GO:0007566 9.61 H3F3A H3F3B MMP9
5 chromatin silencing at rDNA GO:0000183 9.6 H3F3A H3F3B
6 oogenesis GO:0048477 9.58 H3F3A H3F3B
7 tricarboxylic acid cycle GO:0006099 9.58 IDH1 IDH2
8 telomere organization GO:0032200 9.57 H3F3A H3F3B
9 nucleus organization GO:0006997 9.56 H3F3A H3F3B
10 2-oxoglutarate metabolic process GO:0006103 9.55 IDH1 IDH2
11 muscle cell differentiation GO:0042692 9.54 H3F3A H3F3B
12 positive regulation of protein oligomerization GO:0032461 9.52 MMP1 MMP3
13 isocitrate metabolic process GO:0006102 9.48 IDH1 IDH2
14 pericentric heterochromatin assembly GO:0031508 9.46 H3F3A H3F3B
15 regulation of centromere complex assembly GO:0090230 9.4 H3F3A H3F3B
16 negative regulation of chromosome condensation GO:1902340 9.37 H3F3A H3F3B
17 DNA replication-independent nucleosome assembly GO:0006336 9.33 ATRX H3F3A H3F3B
18 telomeric heterochromatin assembly GO:0031509 9.32 H3F3A H3F3B
19 glyoxylate cycle GO:0006097 9.26 IDH1 IDH2
20 extracellular matrix disassembly GO:0022617 9.26 MMP1 MMP3 MMP7 MMP9
21 collagen catabolic process GO:0030574 8.92 MMP1 MMP3 MMP7 MMP9

Molecular functions related to Adult Astrocytic Tumour according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.91 ATRX MMP1 MMP3 MMP7 MMP9 PTEN
2 peptidase activity GO:0008233 9.76 MMP1 MMP3 MMP7 MMP9
3 magnesium ion binding GO:0000287 9.65 IDH1 IDH2 PTEN
4 serine-type endopeptidase activity GO:0004252 9.62 MMP1 MMP3 MMP7 MMP9
5 histone binding GO:0042393 9.58 ATRX H3F3A H3F3B
6 metallopeptidase activity GO:0008237 9.56 MMP1 MMP3 MMP7 MMP9
7 endopeptidase activity GO:0004175 9.54 MMP1 MMP3 MMP9
8 NAD binding GO:0051287 9.52 IDH1 IDH2
9 nucleosomal DNA binding GO:0031492 9.51 H3F3A H3F3B
10 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0016616 9.49 IDH1 IDH2
11 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.16 IDH1 IDH2
12 isocitrate dehydrogenase activity GO:0004448 8.96 IDH1 IDH2
13 metalloendopeptidase activity GO:0004222 8.92 MMP1 MMP3 MMP7 MMP9

Sources for Adult Astrocytic Tumour

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....